Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia

Inclusion Criteria: * M/F 18-70 * 0-1 risk factor, mean LDL-C -/\> 160 and -/\< 250 mg/dL (Visit 2 \& 3) * 2+ risk factors, mean LDL-C -/\> 130 \& -/\< 250 mg/dL (Visit 2 \& 3) * Fasting mean TGs -/\< 400 mg/dL * Understanding and compliance of protocol * sign consent Exclusion Criteria: * Females pregnant, lactating, or CBP who have not been using acceptable contraceptive methods over previous 3 months * Uncontrolled hypertension \>180/95 at screening * Hx of chronic renal insufficiency (serum creatinine \> 2.5 mg/dL) * Hx of liver disease or transaminases \> 1.5 X ULN * Positive for Hepatitis B or C * Major surgery within past 3 mos * Cardiac insufficiency defined as functional Class II-Class IV * Hx of malignancy within previous 5 years * Participation in another investigational drug study within past 6 wks * Serious or unstable medical or psychological condition * Regular alcohol use \> 1 drink per day * Regular consumers of grapefruit juice or medications known to be metabolized by CYP 3A4 * Use of other lipid-lowering meds (washout permitted) * Acute CVD * Diabetes Mellitus * Fasting glucose \>110 mg/dL * BMI -/\> 40 kg/m2 * Significant gastrointestinal symptoms such as IBS * Use of fish oils, niacin, herbal wt. loss products (washout permitted)